STOCK TITAN

Avalo Therapeutics (AVTX) 10-K Filings

AVTX NASDAQ

Here are the 10-K annual reports from Avalo Therapeutics, Inc. (AVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.

Rhea-AI Summary

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on IL-1β‑based treatments for immune‑mediated inflammatory diseases. Its lead antibody, abdakibart (AVTX‑009), is in a Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.

The company is prioritizing completion of this trial and planning potential Phase 3 studies and indication expansion while exploring strategic alternatives for several legacy programs. As of December 31, 2025, Avalo reported $98.3 million in cash, cash equivalents and short‑term investments and $12.9 million in current liabilities, and believes existing funds can support operations into 2028, though additional capital will likely be needed before Phase 3 or broader development.